
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
On June 1, cancer scientists and drugmakers will flock to Chicago for the annual meeting of the American Society of Clinical Oncology (ASCO). The gathering is so prominent that many pharmaceutical companies hold off on releasing data from their clinical trials until the conference. This explains why ASCO is as important to Wall Street folks as it is to the oncology community: Any company that makes a splash at ASCO is likely to see its stock boom.
Read the full story:
Source: Xconomy






